Heterogeneous responses and resistant mechanisms to crizotinib in ALK -positive advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Heterogeneous responses and resistant mechanisms to crizotinib in ALK -positive advanced non-small cell lung cancer

Published:2018-07-06 Issue:9 Volume:9 Page:1093-1103
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Kang Jin¹²,Chen Hua-Jun²,Zhang Xu-Chao²,Su Jian²,Zhou Qing²^ORCID,Tu Hai-Yan²,Wang Zhen²,Wang Bin-Chao²,Zhong Wen-Zhao²,Yang Xue-Ning²,Chen Zhi-Hong²,Ding Yan³,Wu Xue³,Wang Mei⁴,Fu Jian-Gang⁴,Yang Zhenfan⁴,Zhang Xian⁵,Shao Yang W.³⁶,Wu Yi-Long²⁷,Yang Jin-Ji¹²^ORCID

Affiliation:

1. Guangdong Cardiovascular Institute; Guangdong General Hospital and Guangdong Academy of Medical Sciences; Guangzhou China

2. Division of Pulmonary Oncology, Guangdong Lung Cancer Institute; Guangdong General Hospital and Guangdong Academy of Medical Sciences; Guangzhou China

3. Translational Medicine Research Institute; Geneseeq Technology Inc.; Toronto, Ontario Canada

4. BioScience Department; Dizal (Jiangsu) Pharmaceutical Co. Ltd; Shanghai China

5. Medical Department; Nanjing Geneseeq Technology Inc.; Nanjing China

6. School of Public Health; Nanjing Medical University; Nanjing China

7. Medical Research Center; Guangdong General Hospital and Guangdong Academy of Medical Sciences; Guangzhou China

Funder

Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine

National Key Technology R&D Program of the Ministry of Science and Technology of China

Special Fund of Public Interest by National Health and Family Control Committee

National Key R&D Program of China

the Project of the National Natural Science Funding of China

Publisher